Kirkland & Ellis, still among the league table leaders in deal value and volume amidst a down year for M&A and for the firm’s practice in that area, got a nice shot in the arm to start Q4 as the firm represented Bristol Myers Squibb (BMS) in its $13.1 billion acquisition of fellow pharmaceutical company MyoKardia on Monday. The latter was represented by Goodwin Procter.

The deal allows BMS to acquire all of the outstanding common stock shares of MyoKardia for $225 per share in cash. The transaction is expected to close later in Q4 of this year.